Japan Medical Dynamic Marketing, INC. (7600) Stock Price

Japan MDM specializes in importing, developing, manufacturing, and selling medical devices in the orthopedic field. The company primarily handles bone fixation materials, artificial joints, and spinal fixation devices, sourcing products from manufacturers both domestically and internationally for sale within Japan.

The majority of the company's revenue comes from orthopedic-related medical devices. Japan MDM works in partnership with its U.S. subsidiary ODEV Corporation to develop and manufacture products, which are then supplied to Japan MDM. Additionally, ODEV independently sells artificial joints and spinal fixation devices primarily in the U.S. market.

Japan MDM provides high-quality medical devices through sales partnership agreements with manufacturers both in Japan and abroad. Through these partnerships, the company contributes to improving the quality of healthcare in the orthopedic field.

Japan MDM aims to improve patients' quality of life through the development and sales of orthopedic medical devices. The company's management strategy is based on Japan-US joint development, with the goal of providing valuable products to global healthcare markets.

From 2026 to 2028, the company targets increasing net sales to 31,200 million yen. It also plans to raise operating profit margin to 10.6%, pursuing sustainable growth.

In the Japanese market, the company views the expansion of medical needs due to an aging population as a growth opportunity and is continuously introducing new products. To address rising procurement costs from currency fluctuations, it is strengthening its supply chain in the Asia region.

In the US market, the company is advancing supply chain reinforcement and digital technology adoption. It is establishing stable product supply systems and enhancing value delivery in healthcare settings through digital technology utilization.

Japan MDM is promoting new product development and business expansion through a business partnership with Mitsui Chemicals. This initiative aims to build a sustainable growth foundation.

Through the SAICO project, the company is reducing manufacturing costs and improving profitability. It is expanding in-house production ratios and enhancing supply chain resilience.

From a sustainability perspective, the company fulfills social responsibility through ESG activities and aims to contribute to the SDGs. Key priorities include improving patient quality of life, reducing environmental impact, and promoting the active participation of diverse talent.